Genomic Unity® Movement Disorders Analysis

NR006

Genomic Unity® Movement Disorders Analysis is a diagnostic test designed to identify genetic variants that cause movement disorders.

Test Description

Genomic Unity® Movement Disorders Analysis is a targeted test that uses a whole genome platform to detect all major clinically relevant variant types from a single sample. This targeted test focuses on 238 genes associated with movement disorders.

Genomic Unity® Movement Disorders Analysis provides a single, unified clinical report that replaces a battery of tests including: targeted gene panel, single gene analysis and multiplex ligation dependent probe amplification (MLPA), as well as PCR and southern blot tests for short tandem repeat expansions.

When to Order

Order this test when clinical symptoms are consistent with impaired movement including ataxia, imbalance, gait disturbance, spasms and tremors, or other abnormal movements.

Included Genes

ABCB7, ABHD5, ABHD12, ACO2, ADAR, ADCY5, AFG3L2, AHI1, ALDH5A1, ANO3, ANO10, APTX, ARL6, ARL13B, ARSA, ATCAY, ATM, ATN1, ATP1A3, ATP2B3, ATP7B, ATP8A2, ATP13A2, ATXN1, ATXN2, ATXN3, ATXN7, ATXN8OS, ATXN10, BBS1, BBS2, BBS4, BBS5, BBS7, BBS9, BBS10, BBS12, BCAP31, BEAN1, CA8, CACNA1A, CACNA1B, CACNA1G, CACNB4, CAMTA1, CAPN1, CASK, CC2D2A, CCDC88C, CEP41, CEP290, CIZ1, CLCN2, CLN5, CLPP, COASY, COL6A3, COQ8A, COX20, CP, CPLANE1, CWF19L1, CYP2U1, CYP27A1, DCAF17, DDC, DLAT, DNAJC6, DNAJC19, DNMT1, EBF3, EEF2, ELOVL4, ELOVL5, FA2H, FBXL4, FBXO7, FGF14, FLVCR1, FMR1, FTL, FXN, GBA2, GCDH, GCH1, GFAP, GLRA1, GLS, GNAO1, GOSR2, GRID2, GRM1, GSS, HARS2, HEXA, HIBCH, HPCA, HTT, INPP5E, ITM2B, ITPR1, JPH3, KCNA1, KCNC3, KCND3, KCNJ1, KCNMA1, KCTD17, KIF1C, KIF7, KMT2B, LAMA1, LARS2, LMNB1, LRPPRC, LRRK2, MAPT, MARS2, MECR, MKKS, MKS1, MME, MRE11, MTFMT, MTPAP, MTTP, NDUFAF6, NDUFS2, NDUFS4, NDUFS7, NDUFS8, NDUFV1, NKX2-1, NOL3, NOP56 , NOTCH2NLC, NPC1, NPC2, NPHP1, NUBPL, OFD1, OPA1, OPHN1, PANK2, PARK7, PDGFB, PDGFRB, PDYN, PEX7, PEX10, PHYH, PINK1, PLA2G6, PNKD, PNKP, PNPLA6, POLG, POLR3A, POLR3B, PPP2R2B, PRKCG, PRKN, PRKRA, PRRT2, RELN, RFC1, RNF216, RPGRIP1L, RUBCN, SACS, SCN2A, SCP2, SERAC1, SETX, SGCE, SIL1, SLC1A3, SLC2A1, SLC6A3, SLC9A6, SLC16A2, SLC19A3, SLC20A2, SLC25A46, SLC30A10, SLC52A2, SNCA, SNX14, SPG7, SPR, SPTBN2, STUB1, SYNE1, SYNJ1, SYT14, TAF1, TBP, TCTN1, TCTN2, TCTN3, TDP1, TGM6, TH, THAP1, TIMM8A, TMEM67, TMEM138, TMEM216, TMEM231, TMEM237, TMEM240, TOR1A, TOR1AIP1, TPK1, TPP1, TRAPPC11, TRIM32, TTBK2, TTC8, TTC19, TTPA, TUBB4A, TWNK, UBA5, VAMP1, VLDLR, VPS13A, VPS13C,VPS35, WDPCP, WDR45, WDR81, WFS1, WWOX, XPR1, ZFYVE26, ZFHX3, ZNF423

Included Analyses

  • Sequence analysis of movement disorder-associated genes including: single nucleotide variants, deletions, insertions, and characterized intronic variants.
  • Copy number variant analysis of movement disorder-associated genes including: duplications/deletions, mobile element insertions, and inversions.
  • Short tandem repeat (STR) analysis of the ATN1, ATXN1, ATXN2, ATXN3, ATXN7, ATXN8OS, ATXN10, CACNA1A, FGF14, FMR1, FXN, GLS, HTT, JPH3, NOP56, NOTCH2NLC, PPP2R2B, RFC1, TBP, and ZFHX3 genes. (Learn more).

Optionally includes:


Turnaround Time

A report will be issued within 4 weeks. Turnaround time begins when samples and all required documents and approvals are received.

Sample Types

CPT Codes

81177, 81178, 81179, 81180, 81181, 81182, 81183, 81184, 81185, 81188, 81274, 81284, 81343, 81344, 81404, 81405, 81406, 81407, 81408, 81443, 81479

The CPT codes provided are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

Methods and Limitations

Genomic Unity® Movement Disorders Analysis uses a PCR-free whole genome sequencing (WGS) platform paired with our Genomic Intelligence® analytical software.

SNVs:
99.9% sensitivity
99.9% specificity
99.8% positive predictive value

Structural variants:
96% clinical sensitivity

Short tandem repeats:
The false negative rate for repeat expansions has not been determined.

Test limitations:
The ATXN7 and CAMTA1 genes are not fully covered by this test, therefore not all pathogenic variants may be detected.